GURUFOCUS.COM » STOCK LIST » Technology » Software » Hestia Insight Inc (OTCPK:HSTA) » Definitions » Notes Receivable

Hestia Insight (Hestia Insight) Notes Receivable : $0.00 Mil (As of Feb. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Hestia Insight Notes Receivable?

Hestia Insight's Notes Receivable for the quarter that ended in Feb. 2024 was $0.00 Mil.

Hestia Insight's annual Notes Receivable increased from . 20 ($0.00 Mil) to Nov. 2022 ($0.01 Mil) but then declined from Nov. 2022 ($0.01 Mil) to Nov. 2023 ($0.00 Mil).


Hestia Insight Notes Receivable Historical Data

The historical data trend for Hestia Insight's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hestia Insight Notes Receivable Chart

Hestia Insight Annual Data
Trend Nov22 Nov23
Notes Receivable
0.01 -

Hestia Insight Quarterly Data
Feb22 Aug22 Nov22 Feb23 Aug23 Nov23 Feb24
Notes Receivable Get a 7-Day Free Trial 0.01 - - - -

Hestia Insight Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Hestia Insight Notes Receivable Related Terms

Thank you for viewing the detailed overview of Hestia Insight's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Hestia Insight (Hestia Insight) Business Description

Traded in Other Exchanges
N/A
Address
400 S. 4th Street, Suite 500, Las Vegas, NV, USA, 89101
Hestia Insight Inc provides strategic consulting and capital market advisory services for micro, small and medium-sized companies in the healthcare, biotech and fintech sectors. It also provides access to seed capital and mezzanine funding for qualified emerging companies in these industries. The firm derives all of its revenue from consulting services.